This Regulatory Impact Assessment to introduce an incentive to widen the availability of non-prescription medicinal products in line with UK Government objectives to widen availability of medicines for human use; to enhance the safe use of medicines for human use by changes to the patient information and "user testing"; to reinforce the obligations of Marketing Authorisation (MA) holders to provide information impacting on the benefits and risks of medicines human use and so strengthening regulation and increasing patient safety.
Contact details for obtaining hard-copy DH publications.

Useful tips to ensure you get the most from PDFs and the free Reader program. Topics covered include accessibility, troubleshooting and searching files.